Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of Vibrio alginolyticus collagenase in Dupuytren contracture
2022-000666-17Phase 2Completed
- Sponsor
- Fidia Farmaceutici
- Start
- May 2022
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Dupuytren's contracture comparing Vibrio alginolyticus collagenase with Placebo (2 arms). Primary endpoint: Clinical success. Started May 2022; status: completed.
02
Drugs
vibrio alginolyticus collagenase
03
Conditions
Dupuytren's contracture
Beyond the preview
Go deeper on 2022-000666-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000666-17.